Metreleptin

In plain language

Metreleptin is a daily injection for a rare condition called generalized lipodystrophy, in which people have almost no body fat, sold as Myalept. It is a lab-made copy of leptin, the satiety hormone that fat cells normally send to the brain.

In ordinary obesity the brain resists leptin, so leptin injections do not help. But in lipodystrophy there is no fat and therefore almost no leptin, so replacing it is transformative: blood sugar and blood fats normalize and the constant hunger eases.

For students

Metreleptin is recombinant human methionyl-leptin (147 residues plus an N-terminal methionine, about 16 kDa), equivalent to the 16 kDa adipocyte hormone discovered by Jeffrey Friedman's group in 1994 through the ob/ob mouse. Leptin signals long-term energy stores to the hypothalamus; in generalized lipodystrophy (congenital or acquired loss of adipose tissue), leptin is nearly absent, and its downstream signals (including sympathetic and neuroendocrine pathways governing glucose and triglyceride handling) fail.

The pivotal evidence was a single-arm open-label study in generalized lipodystrophy (n=69 across apheresis-type cohorts), showing marked reductions in HbA1c (about 2%) and triglycerides (about 40%), with 12% achieving metabolic normalization; a randomized withdrawal design confirmed the effect by relapse on placebo. The drug carries a boxed warning for anti-metreleptin antibodies that can neutralize endogenous leptin, and for lymphoma observed in a small number of non-indicated patients with acquired partial lipodystrophy, and is distributed through a restricted program.

For researchers and instructors

Biochemistry. The ob/ob mouse and the 1994 positional cloning of the ob gene is a foundational lesson in reverse genetics leading directly to a drug; neutralizing antibodies against a recombinant protein analogizing to the endogenous hormone is the immunology lesson.

Pharmacology. Daily subcutaneous dosing (weight-based for men and women, about 0.04-0.14 mg/kg), titrated to metabolic response; distribution restricted (Myalept REMS-type program); monitoring for infection and lymphoma signs.

Human evidence. The pivotal single-arm study (n=69) plus randomized withdrawal extension; congenital versus acquired lipodystrophy subgroup data; the congenital leptin deficiency literature (a separate ultra-rare condition treated with the same principle) reinforces the mechanism.

Teaching point. Teaches why a drug fails in a common disease (obesity, via resistance) and succeeds in a rare one (absence), a clean lesson in mechanism-based indication selection.